Onxeo: Annual General Meeting of May 16, 2018

PARIS–(BUSINESS WIRE)–Regulatory News:

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO
FR0010095596), a biotechnology company specializing in the development
of innovative drugs in oncology, notably against rare or resistant forms
of cancer, announces that today’s Ordinary Shareholders’ General Meeting
approved all the resolutions submitted to their vote, with over 88% of
favorable votes.

In particular, the Ordinary General Meeting renewed the terms of office
of Mr. Thomas Hofstaetter as director. Mr. Hofstaetter is Chair of the
Onxeo’s Compensation and Business Development Committees.

The quorum of 20.07% did not permit the resolutions to be discussed on
an extraordinary basis. The Company’s shareholders are thus invited to
attend an Extraordinary General Meeting on the second notice which will
be held on June 19, 2018 at 2 pm (CEST) at the Company’s headquarters
(49, boulevard du Général Martial Valin, 75015 Paris, France) to
deliberate on the same agenda.

The vote of the shareholders who voted by mail for the first general
meeting remains valid and counted for the general meeting on the second

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French
biotechnology company developing innovative oncology drugs based on
DNA-targeting and epigenetics, two of the most sought-after mechanisms
of action in cancer treatment today. The Company is focused on bringing
early-stage first-in-class or disruptive compounds (proprietary,
acquired or in-licensed) from translational research to clinical
proof-of-concept, a value-creating inflection point appealing to
potential partners.

Onxeo’s RD pipeline includes belinostat, an HDAC inhibitor
(epigenetics) currently being developed in oral form to be used in
combination with other anti-cancer agents for liquid or solid tumors.
Belinostat is already conditionally FDA-approved in the US as a 2nd
line treatment for patients with peripheral T cell lymphoma and marketed
in the US by Onxeo’s partner, Spectrum Pharmaceuticals, under the name
Beleodaq® (belinostat IV form).

Onxeo is also developing AsiDNA™, a first-in-class DNA break
repair inhibitor based on a unique decoy mechanism. AsiDNA™ has already
successfully completed a Phase I trial in metastatic melanoma via local
administration, and is currently being developed for systemic (IV)
administration in solid tumors.

AsiDNA™ is the first compound generated from platON™, the
Company’s proprietary chemistry platform of decoy oligonucleotides based
on three components, a sequence of double strand oligonucleotides, a
linker and a cellular uptake facilitator. PlatON™ will continue to
generate new compounds that will broaden Onxeo’s pipeline.

For further information, please visit

Forward looking statements
This communication expressly or
implicitly contains certain forward-looking statements concerning Onxeo
and its business. Such statements involve certain known and unknown
risks, uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Onxeo is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a
result of new information, future events or otherwise. For a discussion
of risks and uncertainties which could cause actual results, financial
condition, performance or achievements of Onxeo to differ from those
contained in the forward-looking statements, please refer to the section “Risk Factors” (“Facteurs de Risque“) of the 2017
reference document filed with the Autorité des marchés financiers
on April 25, 2018 under number D.18-0389, which is available on the Autorité
des marchés financiers
website (
or on the Company’s website (

Article source: